Clinical Trial Update: Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tilelizumab with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcinoma that is not completely resectab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Urothelial Carcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Tilelizumab (Tilelizumab)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Status: UNKNOWN